CRISPR-based knockout screening identifies the loss of MIEF2 to enhance oxaliplatin resistance in colorectal cancer through inhibiting the mitochondrial apoptosis pathway

CRISPR-based knockout screening identifies the loss of MIEF2 to enhance oxaliplatin resistance in colorectal cancer through inhibiting the mitochondrial apoptosis pathway

The first-line anticancer agent oxaliplatin (OXL) is the preferred drug for treating colorectal cancer (CRC); however, the development of drug resistance is common in patients treated with OXL, which considerably reduces the efficacy of OXL-based regimens. By performing genome-wide CRISPR/Cas9 libra...

Full description

Bibliographic Details
Main Authors: Chaozheng Xie, Kang Li, Ya Li, Xudong Peng, Biyun Teng, Kuan He, Aishun Jin, Wang Wang, Zhengqiang Wei
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Oncology
Subjects:
CRISPR screens
oxaliplatin
colorectal cancer
MIEF2
mitochondrial apoptosis
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.881487/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.881487/full

Similar Items